Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid s Revenues, Losses Climb in Q4

NEW YORK, Feb. 18 (GenomeWeb News) - Cepheid reported higher revenues as well as losses for the fourth quarter of 2003 yesterday.


The company's revenues for the quarter totaled $5.3 million, up from $4.7 million during the same period last year.


R&D expenses increased slightly, to $4 million, from $3.8 million in the fourth quarter of 2002.


Cepheid's net loss climbed to $4.5 million, or $.13 per share, from $3.5 million, or $.11 per share, during the year-ago period.


As of Dec. 31, the company had cash and cash equivalents of $18.5 million.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.